Related Experiment Video
Updated: Feb 23, 2026
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
Development and Applications of Patient-Derived Xenograft Models in Humanized Mice for Oncology and Immune-Oncology
Bhavna Verma1, Michael Ritchie1, Maria Mancini1
1Champions Oncology, Inc, Baltimore, Maryland.
Abstract:
With the recent approval of four novel immune oncology agents for the treatment of various cancers, the emerging power of this drug class has been substantiated. However, the full potential of such agents is yet to be realized, with only a fraction of the patient population responding to these drugs. A more advanced pre-clinical and translational research platform may increase our understanding of the mechanisms associated with immune-mediated cancer cell death, thereby facilitating the design and development of more generally efficacious agents and drug regimens. Described in this report are the nuances, advantages, and limitations of such a research approach. © 2017 by John Wiley & Sons, Inc.
Insights
Novel immune oncology agents show promise but limited patient response. Advanced pre-clinical and translational research platforms are needed to understand immune-mediated cancer cell death and improve treatment efficacy.
Area of Science:
- Oncology
- Immunology
- Translational Research
Background:
- Recent approval of four novel immune oncology agents validates their therapeutic potential.
- Current immune oncology treatments benefit only a subset of cancer patients, indicating a need for improved strategies.
- Understanding immune-mediated cancer cell death is crucial for advancing oncology treatments.
Purpose of the Study:
- To explore the nuances, advantages, and limitations of advanced pre-clinical and translational research platforms.
- To enhance understanding of immune-mediated cancer cell death mechanisms.
- To facilitate the development of more broadly effective immune oncology agents and treatment regimens.
Main Methods:
- The report describes a research approach focusing on pre-clinical and translational studies.
- The approach aims to elucidate mechanisms of immune-mediated cancer cell death.
- Evaluation of the advantages and limitations of the described research platform is included.
Main Results:
- The study highlights the need for advanced research platforms in immune oncology.
- The described approach can deepen the understanding of how the immune system combats cancer.
- Potential for designing more effective cancer therapies is indicated.
Conclusions:
- Advanced pre-clinical and translational research is essential for realizing the full potential of immune oncology.
- Improved understanding of immune-mediated cell death can lead to more universally effective cancer treatments.
- The discussed research approach offers a pathway to developing superior immune oncology agents and regimens.
